TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1587064

Group type: EXPERIMENTAL
Intervention: 200 mg proguanil alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 mg proguanil with 100 mg racemic mephenytoin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 mg proguanil with 40 mg dextromethorphan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg racemic mephenytoin alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg racemic mephenytoin with 200 mg proguanil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dextromethorphan metabolic ratio included in the model
Number of subjects: 24
Study: 3516017

Group type: EXPERIMENTAL
Intervention: 5% glucose in 0.9% sodium chloride solution (G)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (S)
Number of subjects: 16
Study: 31970448

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training, five times per week
Number of subjects: 71

Group type: COMPARATOR
Intervention: Mobilization exercises (active control group)
Number of subjects: 71
Study: 30199423

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate (SH) + Platelet-Rich Plasma (PRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium Hyaluronate (SH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 0
Study: 28835354

Group type: EXPERIMENTAL
Intervention: Internet self-completion group (n=840)
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Telephone interview group (n=840)
Number of subjects: 1680
Study: 26109727

Group type: EXPERIMENTAL
Intervention: DC-HIV-1 (dendritic cells pulsed with autologous HIV-1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: DC-control (nonpulsed dendritic cells)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DC-HIV-1
Number of subjects: 36

Group type: COMPARATOR
Intervention: DC-control
Number of subjects: 36
Study: 22634831

Group type: EXPERIMENTAL
Intervention: Novel patient-centred communication tool
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (standard communication)
Number of subjects: 146
Study: 21641663

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antipsychotics and anticonvulsants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anticonvulsants and benzodiazepines
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 30
Study: 19701845

Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy volunteers (Control)
Number of subjects: 50
Study: 17050770

Group type: EXPERIMENTAL
Intervention: Behavioral plus medical intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Medical intervention alone
Number of subjects: 21
Study: 14977656

Group type: EXPERIMENTAL
Intervention: Arthroscopic drilling with remaining cartilage (group A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Arthroscopic drilling with removal of remaining cartilage (group B)
Number of subjects: 69
Study: 11732953

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (0.6 mg/kg)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Nebulized dexamethasone sodium phosphate (160 microg)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 9640079

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: IHD with HLP without aspirin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 57
Study: 8477302

Group type: EXPERIMENTAL
Intervention: Preload intervention for restrained eaters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High restrainers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Link between dietary restraint and overeating
Number of subjects: 0
Study: 2868207

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone in addition to high-dose oral prednisolone and standard bronchodilator therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: High-dose oral prednisolone and standard bronchodilator therapy
Number of subjects: 52
Study: 29569793

Group type: EXPERIMENTAL
Intervention: Sleep hygiene and progressive relaxation exercise training
Number of subjects: 161

Group type: COMPARATOR
Intervention: Routine health care (Control)
Number of subjects: 161
Study: 27683869

Group type: EXPERIMENTAL
Intervention: SNAP-Ed intervention (first 4 curriculum lessons)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 575
Study: 24582042

Group type: EXPERIMENTAL
Intervention: Iodixanol-320 at 5.0 mL/sec flow rate (group 3)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Iodixanol-320 at 6.2 mL/sec flow rate (group 2)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Iomeprol-400 at 5.0 mL/sec flow rate (group 1)
Number of subjects: 254
Study: 22483976

Group type: EXPERIMENTAL
Intervention: Intralipid 40 mL/h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextrose 10% 40 mL/h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined Intralipid and dextrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 12
Study: 21266737

Group type: EXPERIMENTAL
Intervention: Heat acclimation (ACC) group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both ACC and CON groups
Number of subjects: 12
Study: 18767339

Group type: EXPERIMENTAL
Intervention: Home and Community Care team intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participatory research
Number of subjects: 0
Study: 16471186

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 60
Study: 11949774

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10051257

Group type: EXPERIMENTAL
Intervention: Oral bambuterol 20 mg once daily in the evening
Number of subjects: 126

Group type: COMPARATOR
Intervention: Inhaled salmeterol 50 micrograms twice daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 126
Study: 7676165

Group type: COMPARATOR
Intervention: Rechtschaffen and Kales criteria
Number of subjects: 55
Study: 2288326

Group type: EXPERIMENTAL
Intervention: Amino acids L-tryptophan and L-tyrosine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 7025830

Group type: EXPERIMENTAL
Intervention: Alcohol (2.5 ml of 40% alc/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31679431

Group type: EXPERIMENTAL
Intervention: Liuweibuqi (LWBQ) capsules (low dose: 1 LWBQ capsule + 8 starch capsules; medium dose: 3 LWBQ capsules + 6 starch capsules; high dose: 9 LWBQ capsules) for 30 days, 3 times a day
Number of subjects: 429

Group type: COMPARATOR
Intervention: Starch capsules (control group)
Number of subjects: 429
Study: 30419868

Group type: EXPERIMENTAL
Intervention: Integrated neuromuscular inhibition technique (INIT) + denneroll cervical traction device
Number of subjects: 120

Group type: COMPARATOR
Intervention: Integrated neuromuscular inhibition technique (INIT)
Number of subjects: 120
Study: 26875161

Group type: EXPERIMENTAL
Intervention: Home fire safety checks program (HFSC)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (similar characteristics to intervention group)
Number of subjects: 2
Study: 24970742

Group type: EXPERIMENTAL
Intervention: Monotherapy (MT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Combination therapy (CT)
Number of subjects: 101
Study: 22124355

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIT) protocols with different work-to-rest ratios (30/30, 60/30, 90/30, 60/60)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIT) protocols
Number of subjects: 8

Group type: COMPARATOR
Intervention: Steady-state exercise at 70% VO2max
Number of subjects: 8
Study: 19129751

Group type: EXPERIMENTAL
Intervention: EVT 301 (25 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EVT 301 (75 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EVT 301 (150 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Selegiline (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EVT 301 (75 mg) in AD subjects
Number of subjects: 20
Study: 17957909

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oral contraceptive (ethinyl estradiol 30 microg and levonorgestrel 150 microg)
Number of subjects: 96
Study: 15140020

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 11
Study: 12008682

Group type: EXPERIMENTAL
Intervention: Insulin glargine (once daily)
Number of subjects: 349

Group type: COMPARATOR
Intervention: NPH insulin (once or twice daily)
Number of subjects: 349
Study: 10477441

Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 975 mg)
Number of subjects: 0
Study: 7539854

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg, 8 mg, and 12 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg and 12 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Doxazosin (all doses)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 2278720

Group type: EXPERIMENTAL
Intervention: High dose metoclopramide (M)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Chloropromazine (C)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Dexamethasone (D) with M
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Chloropromazine (C) with D
Number of subjects: 165
Study: 110185

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 31053887

Group type: EXPERIMENTAL
Intervention: Working Memory Training (WMT)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Neurofeedback Training (NFT) + Working Memory Training (WMT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Visual Search Training (Active Control)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Silent Control Group (no training)
Number of subjects: 140
Study: 30557941

Group type: EXPERIMENTAL
Intervention: MVS + surgical ablation
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Biatrial maze
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 260

Group type: COMPARATOR
Intervention: MVS alone
Number of subjects: 260
Study: 28234969

Group type: EXPERIMENTAL
Intervention: Intervention arm (home-based adherence support)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Standard care/control arm
Number of subjects: 870
Study: 25872794

Group type: EXPERIMENTAL
Intervention: Modified Early Warning System (MEWS) chart with training program
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard care without training
Number of subjects: 114
Study: 23837939

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy (CPT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Daily oral prednisolone
Number of subjects: 60
Study: 21383283

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (BV)
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 1237
Study: 20035587

Group type: EXPERIMENTAL
Intervention: Equasym XL/Metadate CD
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Concerta
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 184
Study: 16872789

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Tai-Chi interest class (comparison group)
Number of subjects: 148
Study: 17163895

Group type: EXPERIMENTAL
Intervention: Systematic literature review process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality assessment questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissemination strategies
Number of subjects: 0
Study: 15543081

Group type: EXPERIMENTAL
Intervention: lercanidipine 10 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: lercanidipine 20 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 23
Study: 10517716

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene (combined 60 mg/d and 120 mg/d)
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7705
Study: 8529160

Group type: EXPERIMENTAL
Intervention: 1% idoxuridine ointment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% trifluorothymidine ointment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1% bromovinyldeoxyuridine (BVDU) ointment
Number of subjects: 80
Study: 1837785

Group type: EXPERIMENTAL
Intervention: high-fat/low-carbohydrate diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: low-fat/high-carbohydrate diet
Number of subjects: 24
Study: 6752467

Group type: EXPERIMENTAL
Intervention: Cefmetazole (CMZ)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Cefazolin (CEZ)
Number of subjects: 172
Study: 29380922

Group type: EXPERIMENTAL
Intervention: Women who developed superimposed pre-eclampsia (SPE)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Women who delivered a small-for-gestational-age (SGA) infant
Number of subjects: 97

Group type: COMPARATOR
Intervention: Women of black ethnicity
Number of subjects: 97
Study: 28705190

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (80 mg once daily)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 406
Study: 26316434

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 1000 mg once daily for 12 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo with recommended diet and lifestyle intervention for 12 months
Number of subjects: 108
Study: 23432755

Group type: EXPERIMENTAL
Intervention: cyclosporine (CSA) and mycophenolate mofetil (MMF) (CSA/MMF, n=151)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: high-level tacrolimus (TAC, 8-12 μg/L) and low-level sirolimus (SIR, 3-7 μg/L) (TACH/SIRL, n=149)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: low-level TAC (3-7 μg/L) and high-level SIR (8-12 μg/L) (TACL/SIR(H), n=140)
Number of subjects: 440
Study: 21242652

Group type: EXPERIMENTAL
Intervention: Strawberry beverage
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 24

Group type: COMPARATOR
Intervention: Strawberry beverage and Placebo beverage
Number of subjects: 24
Study: 19617271

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 842
Study: 17179021

Group type: EXPERIMENTAL
Intervention: DDDR AVSH 60‐130 programming
Number of subjects: 988

Group type: COMPARATOR
Intervention: VVI‐40 programming
Number of subjects: 988
Study: 15138344

Group type: COMPARATOR
Intervention: Hematological supportive care measures including supplementation with iron, human erythropoietin, interleukin 11, granulocyte colony-stimulating factor, and autologous or allogeneic stem cell rescue.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control cohort (matched pairs treated in hospitals not belonging to Jehovah's Witnesses).
Number of subjects: 14

Group type: COMPARATOR
Intervention: Review of 50 pediatric and adult oncological patients belonging to Jehovah's Witnesses from international literature.
Number of subjects: 14
Study: 11789591

Group type: EXPERIMENTAL
Intervention: SKI 306X 200 mg t.i.d.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: SKI 306X 400 mg t.i.d.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: SKI 306X 600 mg t.i.d.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9677830

Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (IgM)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (IgG and IgM) measured at 6 months
Number of subjects: 81
Study: 7997002

Group type: COMPARATOR
Intervention: Air
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 ppb nitrogen dioxide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400 ppb nitrogen dioxide
Number of subjects: 10
Study: 30064403

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP) only
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP) + splint
Number of subjects: 45

Group type: COMPARATOR
Intervention: Splint only
Number of subjects: 45
Study: 27296249

Group type: EXPERIMENTAL
Intervention: Video-based intervention providing access to a virtual online clinic with videos about inpatient rehabilitation (n=394).
Number of subjects: 788

Group type: COMPARATOR
Intervention: No special treatment preparation (control group, n=394).
Number of subjects: 788
Study: 24127304

Group type: EXPERIMENTAL
Intervention: High-risk HPV self-test
Number of subjects: 8800

Group type: COMPARATOR
Intervention: Telephone call
Number of subjects: 8800

Group type: COMPARATOR
Intervention: Standard screening invitation routine (Control)
Number of subjects: 8800
Study: 23687231

Group type: EXPERIMENTAL
Intervention: Dextrose 5% in lactated Ringer's solution (group D; n = 87)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group P; n = 75)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Dextrose 5% in lactated Ringer's solution (group D)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group P)
Number of subjects: 162
Study: 20876454

Group type: EXPERIMENTAL
Intervention: LEN-DEX (lenalidomide plus dexamethasone)
Number of subjects: 192

Group type: COMPARATOR
Intervention: PLC-DEX (placebo plus dexamethasone)
Number of subjects: 192
Study: 18492837

Group type: EXPERIMENTAL
Intervention: CHO+PRO treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: CHO treatment
Number of subjects: 20
Study: 16793810

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg controlled and extended release)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 921
Study: 12705176

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 450 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg
Number of subjects: 12
Study: 10632308

Group type: EXPERIMENTAL
Intervention: Alendronate sodium (5 mg/d for 2 years and 10 mg/d for the third year)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 2027
Study: 14588415

Group type: EXPERIMENTAL
Intervention: Simulators with warning
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Simulators without warning
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study: 8244360

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lactic acid
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 3009077

Group type: EXPERIMENTAL
Intervention: Beet-fibre meal (10.8 g dietary fibre from sugar beet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal (without beet-fibre)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beet-fibre meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 0
Study: 31128875

Group type: EXPERIMENTAL
Intervention: Tdap followed by MCV4-CRM197 (+PCV13) 3–4 weeks later (Group A)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: All three vaccines administered in a single visit (Group B)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: MCV4-CRM197 (+PCV13) followed by Tdap 3–4 weeks later (Group C)
Number of subjects: 107

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 107
Study: 29482642

Group type: EXPERIMENTAL
Intervention: High CXCL13 levels
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: High CXCL13 levels in triple-negative breast cancer (TNBC)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: High CXCL13 levels confirmed in HE10/97 trial patient population with TNBC
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Tumor CD4 content
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: FOXP3 content
Number of subjects: 1010
Study: 27776034

Group type: EXPERIMENTAL
Intervention: Paternal testosterone levels measured at wakeup and bedtime prior to discharge and at 3 additional times at home
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Maternal testosterone levels measured at wakeup and bedtime prior to discharge and at 3 additional times at home
Number of subjects: 86
Study: 25453134

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 43

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 43
Study: 23241361

Group type: EXPERIMENTAL
Intervention: Web-based nursing intervention (SOULAGE-TAVIE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 20139427

Group type: COMPARATOR
Intervention: Oral levonorgestrel (0.75 mg x 4, at 24 h intervals on LH + 1 to LH + 4; n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vaginal levonorgestrel (1.5 mg single dose on LH + 2; n = 7)
Number of subjects: 15